SNTA has has under performed this year and unfortunately there will be some tax loss selling against huge gains made by most other stocks. Without good news there will most likely be continued pressure on the share price due to this trend. If you have a few months foresight, its a buy.
Well stated. A give back of a few bucks is nothing but sell the news garbage and I would be ok with that.
I aint no biotech expert and who really knows how the market reacts to what looks to be strong data but that being said, at this moment I'm pretty comfortable being long.
Shorts.....you must be concerned, eh??
He is picking at KERX's intellectual property claims. He has no argument for how well Zenerex works so now he changes from scientist to patent lawyer and tries to bail himself out.
Has he ever posted why Zenerex will not get a patent?
"Food and drug manufacturers must reveal all chemical and mineral ingredients. Although they are not required to reveal trade secrets and the manner the ingredients are formulated, the base chemical compounds and any added mineral content must be released. Manufacturers are not required to list ingredients in all advertising, but labeling laws require that graphic packaging used to market products have all ingredients clearly listed."
Layman's view... Acthar is neither a chemical or a mineral. As for trade secrets, I have no idea. Thoughts?
I think you need to let Bailey just do what he does best and that is to just sit back and let the act play out.
It worked before and will work again. QCOR has a killer product and doesn't need to pull strings to put up big numbers. Use this noise to accumulate stock.
Disclaimer...I own too much of QCOR but only because I'm a believer.
Or the socialist police will be on you like flies on shizzle. Its all a joke but just part of the new Amerika.
All things said, this will be very short lived as the numbers QCOR puts up will win every time.
Was this the info that drove the stock and can you explain the case for me? I didn't know about it.
I don't see why it would matter how many conditions Acthar treats. If these illnesses were all treated by different drugs from different companies then there would be no issue. IMO just because QCOR has one drug that that treats all of these small needs, there should be no restriction on total sales.
Layman's POV but that's my thought.
My guess is that Alpert sent the shorts in to the meeting and when he got pinched, he threw a hissy fit and wrote the lameass article.
I posted last week that there would be very little real news issued during the presentation and JFK thought I might be a basher. The question is do we well off tomorrow because of this or do we continue to move up based on the decent momo that we have?
SNTA IR told me "next batch of data will be released sometime in Q4 of 2013". Simple as that.
Like Allen said in the Hangover when they fed the lion the dope..."We wait".